Sugi Predict

Sugi Predict / Compounds / SCHEMBL708709

SCHEMBL708709

SCHEMBL708709

CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccc(C(F)(F)F)n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AGTR2 P50052 9/20 0.70
▸ AGTR1 P30556 2/20 0.70
▸ CYP2C9 P11712 2/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ GMNN O75496 1/20 0.61
▸ USP2 O75604 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ TP53 P04637 1/20 0.61
▸ CYP1A2 P05177 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ CYP2D6 P10635 1/20 0.61
▸ MAPT P10636 1/20 0.61
▸ TSHR P16473 1/20 0.61
▸ NFKB1 P19838 1/20 0.61
▸ APEX1 P27695 1/20 0.61
▸ CYP2C19 P33261 1/20 0.61
▸ THPO P40225 1/20 0.61
▸ MTOR P42345 1/20 0.61
▸ RECQL P46063 1/20 0.61
▸ RAB9A P51151 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1718929 0.92 AGTR2 (0.71) AGTR2AGTR1CYP2C9CYP2B6
SCHEMBL707904 0.86 AGTR2 (0.76) AGTR2AGTR1CYP2C9MEN1GMNN
SCHEMBL709767 0.85 AGTR2 (0.74) AGTR2AGTR1CYP2C9MEN1GMNN
SCHEMBL710640 0.84 AGTR2 (0.75) AGTR2AGTR1CYP2C9MEN1GMNN
Buloxibutid SCHEMBL30718088 0.83 AGTR2 (0.98) AGTR2AGTR1CYP2C9CYP2B6
SCHEMBL25576351 0.83 AGTR2 (0.80) AGTR2AGTR1CYP2C9MEN1GMNN
Buloxibutid SCHEMBL557591 0.82 AGTR2 (1.00) AGTR2AGTR1CYP2C9CYP2B6
SCHEMBL23121018 0.82 AGTR2 (1.00) AGTR2AGTR1CYP2C9MEN1GMNN
Buloxibutid SCHEMBL26934181 0.82 AGTR2 (0.98) AGTR2AGTR1CYP2C9CYP2B6
SCHEMBL708270 0.82 AGTR2 (0.72) AGTR2AGTR1CYP2C9MEN1GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1529697-B Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB 2010-09-22 — — CN claimed
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists VICORE PHARMA AB 2009-12-31 — — US claimed
EP-1395566-B1 TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2007-09-12 — — EP claimed
CN-1529697-A Tricyclic compounds useful as angiotensin II agonists ά�ƶ�ҩ�﹫˾ 2004-09-15 — — CN claimed
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2004-08-26 — — US claimed
US-8124638-B2 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2012-02-28 — — US disclosed
CN-1529697-B Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB 2010-09-22 — — CN disclosed
US-7652054-B2 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2010-01-26 — — US disclosed
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists VICORE PHARMA AB 2009-12-31 — — US disclosed
EP-1395566-B1 TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2007-09-12 — — EP disclosed
CN-1529697-A Tricyclic compounds useful as angiotensin II agonists ά�ƶ�ҩ�﹫˾ 2004-09-15 — — CN disclosed
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2004-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists AGTR1, AGTR2, NPY2R AGTR2 2/4885AGTR1 1/4885CYP2C9 1541/4885
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists AGTR2, AGTR1, NPY4R AGTR2 1/4885AGTR1 2/4885CYP2C9 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.